NanoLogix Company Updates

2013

• Dec 24, 2013:
  
  

  NanoLogix is pleased to announce the addition of two new members to the Science Advisory Board:

  
  

  Dr. Sebastian Faro rejoins the SAB after an absence of over a year when he resigned due to a policy change at UTHSC-Houston that required all personnel affiliated with UTHSC to shed any corporate associations. Dr. Faro is now affiliated with The Woman's Hospital of Houston, which does not restrict physicians. associations. The company welcomes Dr. Faro back to the Science Advisory Board.

  
  

  "I am excited to be rejoining the scientific advisory board. I am looking forward to the build out of our new laboratory adjacent to our clinic offices at Woman.s Hospital. We have made significant and dramatic progress in the rapid detection and identification not only of GBS, but also Enterococcus and N. gonorrhoeae. I look forward to working with you and the Scientific Advisory Board.The future is exciting."

  
  Michelle Durkin. Chief of Laboratory Operations at NanoLogix. Michelle assumes the position of Science Advisory Board Coordinator. Michelle has been with NanoLogix for over two years and has contributed greatly to the success of the company.
  
  "I am honored to join the NanoLogix Scientific Advisory Board and also to take the position of Coordinator. NanoLogix has made huge strides in the past two years and the growth over the past few months has been remarkable. I am excited to see NanoLogix breaking into several different markets, and it is exciting to see the strong interest that many share for our technology. I am looking forward to 2014, as I feel it will be extremely rewarding for the company. I am very pleased to be part of this talented group of individuals and am happy to have just signed a three year contract renewal which assures that I will continue to contribute to NanoLogix. success and growth."
  


• Dec 15, 2013:
  NanoLogix Inc. Russia has granted and issued a patent to NanoLogix for its BNP detection technology. This is the second international patent granted for BNP in 2013, with grant and issuance by Japan earlier this year.
  


• Dec 15, 2013:
  NanoLogix Inc. In the World Health Organization's Global Tuberculosis Report 2013 on page 87, NanoLogix' BNP Middlebrook test has been mentioned as a "culture based technology in early development". The BNP Middlebrook provided evidence of live TB growth in 5 days in tests by the world's largest private Research and Development corporation. Tests for screening for TB in blood at the same facility using NanoLogix BNF technology provided positive results in roughly 1-1/2 hours. Both test results are important in the battle against TB, with standard sputum culture results taking roughly three weeks and rapid blood screening tests, critical in the diagnosis of pediatric TB, as children do not produce sputum, taking many hours.
  In the World Health Organization's Global Tuberculosis Report 2013 on page 87, NanoLogix' BNP Middlebrook test has been mentioned as a "culture based technology in early development"


• Dec 4, 2013:
  NanoLogix Inc. Announces additional product offerings with E-Beam sterilization process
  NanoLogix and Saudi Company To Work Together for Distribution of NanoLogix Products in the Arabian Gulf Region


• August 18, 2013:
  Dr Jonathan Faro of the UTHSC at Houston presented two posters at the IDSOG meeting in Albuquerque showing the results of tests with NanoLogix BNF and new Multiwell N-Assay diagnostics. The N-Assay delivered 30 minute results for detection and identification of Group B Streptococcus (GBS) while the BNF provided detection, identification, and determination of sensitivity to clindamycin antibiotic in 6 - 6.5 hours. Both tests are significantly faster than the standard tests in use, which take 48-72 hours for the same results. The significance of the results and impact upon screening for GBS in pregnancies, and potentially in the elderly and immuno-compromised patients of all ages, is tremendous.
  1. FC-Fragment.pdf
  2. Clinda.pdf


• August 06, 2013:
  NanoLogix Inc. Report on technologies
  To assist in the commercialization, production, and marketing of NanoLogix BNP, N-Assay, BNF, and..


• June 21, 2013:
  NanoLogix Inc. Report on technologies
  June 21, 2013 Video instructional update for use of BNP kits


• 
  

  Jun 11, 2013: Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 Read more>>>

  
  


• April 30, 2013:
  NanoLogix Inc. Report on technologies
  
  
  

  The past fifteen months have been highly successful for NanoLogix as it continues to develop new products and new markets. In that time, the company has advanced in a number of important areas, including development of new technologies, increasing sales and customer bases, and garnering substantial recognition in published research on NanoLogix products and techniques. We are excited by these developments and by additional new opportunities.

  
  

  New Technologies

  
  

  The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.

  
  

  In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, but not in other areas or regions that are less developed.

  
  

  Scholarship and Research on NanoLogix Technologies

  
  

  In December 2012 a paper was published in the Journal of Microbial and BioChemical Technology detailing preliminary results using the company’s BNP technology for detection of live Tuberculosis through culture. Those results were obtained in five days, compared to weeks with standard culture methods. http://www.omicsonline.org/1948-5948/pdfdownl...04-147.pdf In January of 2013 the final results of a 356 patient clinical study by researchers at the University of Texas Health Science Center at Houston were published in the Journal of Infectious Diseases in Obstetrics and Gynecology detailing the results obtained with NanoLogix’s BNF technology for rapid detection of Group B Streptococcus in pregnant patients. http://www.hindawi.com/journals/idog/2013/367935/

  
  

  New License and Patents

  
  

  The company has been recently granted a patent for its BNP technology in Japan, its BNC technology in China, and has indications that it will soon receive a grant of patent in the EU for BNP. Patents are pending for BNP in the US, China, Russia, India, Brazil and the EU. Patents for BNF technology are pending in the US, China, the EU, Japan, India and Brazil. A US patent was granted in April 2013 for the FlatPack® packaging technology, to which NanoLogix has an exclusive license. The FlatPack® technology has been pivotal to the sales of filled Petri plates by the company, with extraordinary increases in shelf life, durability of product during shipping, and numerous other advantages over all competitors’ similar products. We have exhibited our BNF and BNP and licensed FlatPack® Petri technologies at multiple events: the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Meeting and the Food Safety Summit, both in Washington, D.C., and at the ASM Annual Meeting in San Francisco

  
  

  Marketing

  
  

  In 2013, NanoLogix contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders (KOLs) and executives in multiple health, industrial, pharmaceutical and food sectors. The marketing team is composed of current or former directors and managers of two national and international pharmaceutical corporations. This alliance continues the transition of the Company from a primary focus on research and development to one of production and marketing. There will be a continued science emphasis upon product Quality Assurance and Quality Control and also water quality test development with the US EPA. This new focus is resulting in a reallocation of resources with a heavy emphasis upon increased high level marketing on multiple fronts.

  
  

  Financial Matters

  
  

  As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000.  That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors *** the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.

  
  

  In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.

  
  
  
  


• April 05, 2013:
  NanoLogix plans to begin marketing this summer of their new N-Assay Multiwell Diagnostic test. The N-Assay is a machine-readable test that will be available in an assortment of size configurations for detection and identification of a variety of bacteria. Tests to date have provided consistent results in as little as 30 minutes with both high sensitivity and specificity.


• April 02, 2013: